Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 12, 2013, Pages 1829-1833

  Lee, Kang Moon ^a   Jeen, Yoon Tae ^b   Cho, Ju Yeon ^c   Lee, Chang Kyun ^d   Koo, Ja Seol ^b   Park, Dong Il ^e   Im, Jong Pil ^f   Park, Soo Jung ^g   Kim, You Sun ^h   Kim, Tae Oh ^h   Lee, Suck Ho ^j   Jang, Byung Ik ^k   Kim, Ji Won ^f   Park, Young Sook ^m   Kim, Eun Soo ^l   Choi, Chang Hwan ⁱ   Kim, Hyo Jong ^d  

^a The Catholic University of Korea   (South Korea)

^b Korea University   (South Korea)

^c Samsung Medical Center   (South Korea)

^d Kyung Hee University   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Seoul National University   (South Korea)

^g Yonsei University   (South Korea)

^h Inje University College of Medicine   (South Korea)

ⁱ Chung Ang University   (South Korea)

^j Soonchunhyang University   (South Korea)

^k Yeungnam University   (South Korea)

^l Keimyung University   (South Korea)

^m Eulji University   (South Korea)

more..

Author keywords

Efficacy; Infliximab; Predictor of response; Safety; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; HEMOGLOBIN; INFLIXIMAB; LIVER ENZYME;

ADULT; ANEMIA; ARTICLE; BALLOON DILATATION; DEMYELINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; INFUSION RELATED REACTION; INTESTINE PERFORATION; KOREA; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SERUM SICKNESS; SIDE EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIRUS REACTIVATION;

EFFICACY; INFLIXIMAB; PREDICTOR OF RESPONSE; SAFETY; ULCERATIVE COLITIS;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897658333     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12324     Document Type: Article

References (27)

1. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 2007; 5: 103-110.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
3. Rutgeerts P, Sandborn WJ, Feagan BG etal. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-2476.
4. Colombel JF, Rutgeerts P, Reinisch W etal. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201.
5. Mortensen C, Caspersen S, Christensen NL etal. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J. Crohns Colitis 2011; 5: 28-33.
6. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J. Gastroenterol. Hepatol. 2012; 27: 487-492.
7. O'Donnell S, Murphy S, Anwar MM etal. Safety of infliximab in 10 years of clinical practice. Eur. J. Gastroenterol. Hepatol. 2011; 23: 603-606.
8. Su C, Salzberg BA, Lewis JD etal. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 2002; 97: 2577-2584.
9. Sandborn WJ, Rutgeerts P, Feagan BG etal. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260.
10. Ferrante M, Vermeire S, Fidder H etal. Long-term outcome after infliximab for refractory ulcerative colitis. J. Crohns Colitis 2008; 2: 219-225.
11. Oussalah A, Evesque L, Laharie D etal. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am. J. Gastroenterol. 2010; 105: 2617-2625.
12. Ng SC, Tsoi KK, Kamm MA etal. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm. Bowel Dis. 2012; 18: 1164-1176.
13. Yang SK, Yun S, Kim JH etal. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm. Bowel Dis. 2008; 14: 542-549.
14. Yang SK, Hong WS, Min YI etal. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong district, Seoul, Korea, 1986-1997. J. Gastroenterol. Hepatol. 2000; 15: 1037-1042.
15. Satsangi J, Silverberg MS, Vermeire S etal. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
16. Stange EF, Travis SP, Vermeire S etal. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J. Crohns Colitis 2008; 2: 1-23.
17. Ferrante M, Vermeire S, Katsanos KH etal. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 2007; 13: 123-128.
18. Jürgens M, Laubender RP, Hartl F etal. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol. 2010; 105: 1811-1819.
19. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
20. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A etal. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55: 1609-1614.
21. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel patient population. Clin. Gastroenterol. Hepatol. 2012; 10: 1002-1007.
22. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 28: 674-688.
23. Colombel JF, Sandborn WJ, Reinisch W etal. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 362: 1383-1395.
24. Walch A, Meshkat M, Vogelsang H etal. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J. Crohns Colitis 2010; 4: 398-404.
25. Jürgens M, Mahachie John JM, Cleynen I etal. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 2011; 9: 421-427.
26. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment. Pharmacol. Ther. 2012; 35: 568-576.
27. Henriksen M, Jahnsen J, Lygren I etal. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518-1523.